Cardiovascular Program

About StrideBio

StrideBio, founded in 2015 and based in Durham, NC, is a private, pre-revenue biotech focused on advancing gene therapy through its novel AAV engineering platform. The company's STRIVE platform utilizes structure-inspired design to create capsids with improved tropism, reduced pre-existing immunity, and enhanced manufacturability compared to natural AAV serotypes. Its lead programs target genetic conditions like Friedreich's ataxia and a severe pediatric epilepsy (SLC13A5 deficiency), with a broader pipeline in discovery and preclinical stages. StrideBio has secured significant venture funding and established key partnerships with Takeda and Arbor Biotechnologies to validate and expand its platform's reach.

About Helixomer

Helixomer is a private, preclinical biotech firm pioneering a novel drug design platform that combines RNA origami (RNAO) with aptamers to create more effective nanodrugs. Its core technology aims to overcome the historical limitations of aptamers—such as low efficacy and rapid clearance—by arranging multiple aptamers on a stable, non-immunogenic RNA scaffold. The company is applying this modular, 'plug-and-play' platform to build a pipeline in oncology, neurodegenerative disorders, and cardiovascular disease, positioning itself as a next-generation RNA medicine developer.

Therapeutic Areas